Voyager Therapeutics, Inc. (VYGR)

Voyager Therapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Year	2023	2022	2021	2020	2019
Cash & Equivalents	68.8	98.96	117.43	104.44	86.04
Short-Term Investments	162.07	19.89	15.11	76.7	195.49
Cash & Cash Equivalents	230.88	118.85	132.54	181.14	281.53
Cash Growth	94.26%	-10.33%	-26.83%	-35.66%	80.69%
Receivables	83.49	0.26	0.73	8.01	18.5
Other Current Assets	5.32	5.39	3.43	8.62	4.63
Total Current Assets	319.68	124.5	136.7	197.77	304.66
Property, Plant & Equipment	30	33.34	55.38	61.5	46.46
Long-Term Investments	0	0	0	0	1.92
Other Long-Term Assets	1.59	1.52	1.78	2.32	1.72
Total Long-Term Assets	31.6	34.86	57.16	63.82	50.1
Total Assets	351.28	159.36	193.86	261.58	354.76
Accounts Payable	1.6	2.57	0.57	0.63	4.07
Deferred Revenue	75.24	65.83	42.1	43.82	194.49
Other Current Liabilities	-12.34	4.2	8.31	-17.69	-122.55
Total Current Liabilities	64.51	72.59	50.98	26.77	76.01
Other Long-Term Liabilities	50.45	27.75	47.82	80.5	179.24
Total Long-Term Liabilities	50.45	27.75	47.82	80.5	179.24
Total Liabilities	114.96	100.34	98.8	107.26	255.25
Retained Earnings	-261.18	-393.51	-347.1	-275.91	-312.65
Comprehensive Income	-0.05	-0.22	-0.14	-0.13	-0.1
Shareholders' Equity	236.32	59.02	95.06	154.32	99.51
Net Cash / Debt	230.88	118.85	132.54	181.14	281.53
Net Cash / Debt Growth	94.26%	-10.33%	-26.83%	-35.66%	80.69%
Net Cash Per Share	5.18	3.10	3.52	4.85	7.84
Working Capital	255.18	51.91	85.72	171	228.65
Book Value Per Share	5.49	1.54	2.52	4.16	2.77

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).